Francis Knuettel II - Feb 21, 2024 Form 4/A Insider Report for Chromocell Therapeutics Corp (CHRO)

Role: CEO, Pres., CFO Treas & Secty
Signature: /s/ Francis Knuettel II
Stock symbol: CHRO
Transactions as of: Feb 21, 2024
Transactions value $: $0
Form type: 4/A
Date filed: 6/18/2024, 08:07 PM
Date Of Original Report: Feb 21, 2024
Previous filing: Feb 15, 2024
Next filing: Jun 18, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CHRO	Employee Stock Option	Award		+2.78K	+12.5%		25K	Feb 21, 2024	Common Stock	2.78K	$22.68	Camden Capital LLC	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On February 23, 2024, the Reporting Person filed a Form 4 which inadvertently reported that, Camden Capital LLC disposed of 2,778 shares of the Issuer's common stock. In fact, following the grant of stock options to Camden Capital LLC, it acquired 2,778 shares of the Issuer's common stock at an exercise price of $22.68 per share, which became exercisable upon the closing of Issuer's initial public offering.
F2	The securities are held by Camden Capital LLC. The Reporting Person, as the manager of Camden Capital LLC, is deemed to be a beneficial owner of these securities.

Content

On February 23, 2024, the Reporting Person filed a Form 4 which inadvertently reported that, Camden Capital LLC disposed of 2,778 shares of the Issuer's common stock. In fact, following the grant of stock options to Camden Capital LLC, it acquired 2,778 shares of the Issuer's common stock at an exercise price of $22.68 per share, which became exercisable upon the closing of Issuer's initial public offering.

The securities are held by Camden Capital LLC. The Reporting Person, as the manager of Camden Capital LLC, is deemed to be a beneficial owner of these securities.